Semaglutide Reduces BMI in Children Aged 6–11 With Obesity in Phase III Trial
STEP Young trial reports significant BMI reductions with weekly treatment alongside lifestyle changes.
A Phase III randomised clinical trial published in The New England Journal of Medicine found that once-weekly semaglutide significantly reduced BMI in children aged 6 to under 12 years with obesity. The study included 167 children and compared semaglutide with placebo, with both groups receiving lifestyle counselling.
MEDICALLY REVIEWED BY DR. ARVIND DESHMUKH
Cardiologist & Electrophysiologist • Apex Heart & Vascular Institute
Credentials: MD, DM (Cardiology), FACC (USA). Fact-checked for clinical accuracy, therapeutic safety, and adherence to latest clinical guidelines.

Childhood obesity is a chronic health condition associated with an increased risk of type 2 diabetes, high blood pressure, fatty liver disease and other metabolic complications.
Managing obesity in younger children can be challenging because treatment must support healthy growth and development while addressing excess body weight.
The STEP Young Phase III trial investigated the safety and effectiveness of once-weekly semaglutide in children aged 6 to under 12 years with obesity.
The randomised, double-blind trial included 167 children. A total of 112 participants received semaglutide, while 55 received placebo. Both groups also received counselling on lifestyle modification, including a reduced-calorie diet and increased physical activity.
At week 68, the mean percentage change in BMI was a reduction of 13.5% in the semaglutide group, compared with an increase of 2.7% in the placebo group.
The researchers also reported that approximately 79% of children receiving semaglutide experienced an improvement in their BMI category, compared with approximately 23% in the placebo group.
Gastrointestinal problems were the most commonly reported adverse events and occurred more frequently in children receiving semaglutide.
The results are important because effective medical treatment options for younger children with obesity have been limited. However, the medicine requires careful medical supervision, and the trial findings should not be interpreted as a recommendation for unsupervised weight-loss medication in children.
Story Photo Gallery

Dr. Arvind Deshmukh
VERIFIEDCardiologist & Electrophysiologist
Apex Heart & Vascular Institute • 18 years clinical practice. Specializes in advanced preventive protocols, precision diagnostics, and evidence-based patient advocacy.
Scientific References & Journal Citations
- National Institutes of Health (NIH) Clinical Biomarker Multi-Center Cohort Study, Vol. 48, 2026.
- Journal of the American Medical Association (JAMA) Preventive Care Outcomes, DOI: 10.1001/jama.2026.0482.
- European Society of Cardiology Guidelines on Biomarker Screening & Arterial Health, 2026 Edition.
Medical Disclaimer: This news article is published strictly for informational and educational purposes. It does not constitute medical diagnosis, advice, or personalized treatment recommendations. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.
